Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"TAI" is a non-specific term that, in the provided clinical contexts, refers to two distinct entities. In oncology, particularly in trials involving non-small cell lung cancer (NSCLC), it is a common abbreviation for **Transcatheter Arterial Infusion**, a localized drug delivery procedure used to administer chemotherapy directly into the blood vessels supplying a tumor. In the context of proctology and traditional Chinese medicine (TCM), "TAI" (often appearing as "Anal Tai" or "Gangtai") refers to **Gangtai** (肛泰), a branded multi-ingredient herbal formulation used to treat hemorrhoids, anal fissures, and anal sinusitis. The Gangtai formulation typically includes ingredients such as *Sanguisorba officinalis* (Burnet), *Galla Chinensis*, *Borneol*, *Berberine Hydrochloride*, and *Papaverine Hydrochloride*, which collectively exert anti-inflammatory, analgesic, hemostatic, and antispasmodic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TAI.